Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (NCT06598306)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (6 items).
Location: University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Participants that have received prior DLL3 targeted therapy.
- Participants with untreated or symptomatic brain metastases or those requiring therapy with steroids.
- Note: Participants with asymptomatic brain metastatic lesions are allowed following definitive treatment (Amgen Medical Monitor may approve untreated, asymptomatic brain metastasis if local therapy is not required per investigator judgment).
- Participants with leptomeningeal disease.
- Participants with baseline oxygen requirement.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California
- University of Illinois Chicago — Chicago, Illinois
- Trinity Health Saint Joseph Mercy Ann Arbor — Ann Arbor, Michigan
- Avera Cancer Institute — Sioux Falls, South Dakota
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Swedish Cancer Institute — Seattle, Washington
- Chris OBrien Lifehouse — Camperdown, New South Wales
- Calvary Mater Newcastle Hospital — Waratah, New South Wales
- The Alfred Hospital — Melbourne, Victoria
- Universitair Ziekenhuis Gent — Ghent,
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg — Leuven,
- Centre Hospitalier Universitaire de Liege - Sart Tilman — Liège,
- Jilin Cancer Hospital — Changchun, Jilin
- Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality
- Universitaetsklinikum Regensburg — Regensburg,
- Universitaetsklinikum Wuerzburg — Würzburg,
- Okayama University Hospital — Okayama, Okayama-ken
- Wakayama Medical University Hospital — Wakayama, Wakayama
- Uniwersyteckie Centrum Kliniczne — Gdansk,
- Instytut Centrum Zdrowia Matki Polki — Lodz,
- Wojewodzki Szpital im Sw Ojca Pio w Przemyslu — Przemyśl,
- Hospital Regional Universitario de Malaga — Málaga, Andalusia
- Hospital Universitari Vall d Hebron — Barcelona, Catalonia
- Hospital Universitari i Politecnic La Fe — Valencia, Valencia
- Hospital Universitario 12 de Octubre — Madrid,
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Extensive Stage Small Cell Lung Cancer
- To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC — Birmingham, Alabama
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab — Orlando, Florida
- First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) — Los Angeles, California
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer — Chicago, Illinois
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) — Gilbert, Arizona
Explore by condition: All Extensive Stage Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.